pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vyalev
drug
save

(foscarbidopa + foslevodopa)

Marketedupdated 6mo ago
by $ABBV AbbVie Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • drugVYALEV4 co-mentions · 2 sources
  • tagApproval4 co-mentions · 2 sources

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

indications

investigational
Parkinson's Disease

all catalysts(2)

approval · 2
Oct 16, 2024
approval
$ABBV295.03+0.20%
2y ago
VYALEV (FOSCARBIDOPA) — FDA approval
(foscarbidopa + foslevodopa)
→
Mar 19, 2026
approval
$ABBV295.03+0.20%
8mo ago
VYALEV (FOSCARBIDOPA) — FDA approval
(foscarbidopa + foslevodopa)
→

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 16, 2027
334 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Jun 10, 2040method-of-use (U-4030)US 12251365
  • Oct 21, 2035formulationUS 10174061
  • Oct 21, 2035compositionUS 10730895
  • Oct 21, 2035compositionUS 9446059

FDA exclusivities (1)

  • Oct 16, 2027NPNP334d

News(2)

  • AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
    Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.
    biospace · 16d ago
  • AbbVie shares pressured as Q2 I&I beat falls below investor expectations
    AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
    biospace · 3mo ago
brand
Vyalev
generic
(foscarbidopa + foslevodopa)
MOA
12.1 Mechanism of Action VYALEV is a prodrug combination of foscarbidopa (carbidopa-4´-monophosphate) and foslevodopa (levodopa-4´-monophosphate). Foscarbidopa and foslevodopa are converted in vivo to carbidopa and levodopa. Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats symptoms of Parkinson's disease.
indication
Parkinson's Disease
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 37m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?